Answers are grounded in this paper and cite their sources.
Background Fasting insulin modulates growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) synthesis, but its relation to early height response to recombinant human GH (rhGH) therapy is unclear. We examined this in children with idiopathic short stature (ISS). Methods This single-center retrospective cohort study reviewed records of children aged 3–14 years who started rhGH monotherapy for ISS at a tertiary pediatric endocrinology center between December 2018 and December 2024. Children with another identifiable cause of short stature, obesity, diabetes, uncontrolled hypothyroidism, Turner syndrome or concurrent gonadotropin-releasing hormone agonist therapy were excluded. The primary outcome was the change in height standard deviation score (SDS) from baseline to 3 months, and the secondary outcomes were the 3-month height gain and the change in height SDS from baseline to 6 months. Baseline fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) were related to the outcomes by Spearman correlation and by linear regression adjusted for age, sex, baseline height SDS and baseline IGF-1 SDS, with a sensitivity model adding rhGH dose and Bonferroni correction. Results Of 224 eligible children, 169 with complete baseline and 3-month data formed the primary analysis set, and 210 with 6-month data were analyzed for the 6-month outcome. Baseline fasting insulin correlated with the 3-month change in height SDS [Spearman correlation coefficient (rs) = 0.667], the 3-month height gain (rs = 0.331) and the 6-month change in height SDS (rs = 0.500), all p < 0.0001 and significant after Bonferroni correction. In multivariable regression (coefficient of determination R 2 = 0.209), each 1 μ U/mL higher fasting insulin was associated with a 0.034 greater 3-month change in height SDS (95% confidence interval [CI] 0.018–0.050, p < 0.0001), and the association persisted after adjustment for rhGH dose (0.036, 95% CI 0.020–0.052). Conclusions Baseline fasting insulin was associated with early height SDS gain during rhGH therapy in children with ISS after adjustment for age, sex, baseline height SDS and IGF-1 SDS, although residual confounding, particularly by pubertal status, cannot be excluded. These retrospective, unvalidated findings are hypothesis-generating and do not support using fasting insulin to guide rhGH dosing.
No takes yet. Share an insight, caveat, or question.
Ju et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: